Chiron Corporation

Cetus Corporation

Cetus Oncology Corporation

Other

G.d. Searle LLC

Novartis Vaccines & Diagnostics, Gmbh

Robert F Halenbeck

Kirston E Koths

George A Martin

Martha B Ladner

Ernest S Kawasaki

Mazie Yee Coyne

Eric W Taylor

Janelle A Noble

Alice M Wang

Kirk William Johnson

Michael Kriegler

Bao-lu Chen

Glenn J Dorin

Carl F Perez

Walter J Laird

Cynthia A Cowgill

David A Jewell

Gary V Johnson

Hassan Madani

Mark E Gustafson

Gary S Bild

Bo H Arve

Gregory L Pattison

Clayton L Casipit

Michael Tsang

Janelle N Van Arsdell

Maninder S Hora

Francis P McCormick

Sung-Hou Kim

Anna Lisa Fear

Rajsharan K Rana

Jarmila Jancarik

Maninder S Hoba

Jayvardhan Pandit

Ralph Yamamoto

Andrew Bohm

Mary M Trahey

Lewis T Williams

David B Ring

Michael A Innis

Bonnee Rubinfeld

David F Mark

Ze'ev Shaked

Nandini Katre

Michael G Kunitani

Gail L Wong

Robin Clark

Peter M Fernandes

Michael J Knauf

Robert J Goodson

Flint Smith

Dong Wei

Edward C O'Rourke

Rejsharan K Bana

Jan Tuttleman

Kriston Koths

Raisharan K Rana

Danutee Nitecti

Frank P McCormick

Peter C McCabe

Joseph W Wrin

Compositions are described that are suitable for formulating TFPI. Solubilizers and stabilizers facilitate the preparation of pharmaceutically acceptable compositions of TFPI at various concentrations.

Formulation, solubilization, purification, and refolding of tissue factor pathway inhibitor

A stress-phosphorylated endoplasmic reticulum protein, Nogo B, is provided. The protein is hyperphosphorylated as a result of exposure of cells to stress. Two transcripts of Nogo B are identified in human tissues, and the longer transcript is predominant in human brain tumor samples.

Protein associated with cell stress response

A method of modifying protein solubility employs polyionic polymers. These facilitate the solubilization, formulation, purification and refolding of proteins especially incorrectly folded proteins and aggregated proteins. Compositions are described that are suitable for formulating TFPI. The compositions allow preparation of pharmaceutically acceptable compositions of TFPI at concentrations above 0.2 mg/mL and above 10 mg/mL.

Methods and materials are disclosed for the production of purified, active recombinant human neutrophil protease, PR-3, via activation of a pro-form herein referred to as proPR-3. Human PR-3 is useful for discovering inhibitors of excessive release of mature, active TNF&agr;. Also disclosed are methods for the identification of inhibitors of the conversion of the pro-form of TNF&agr; to its mature active form.

Recombinant PR-3 and assays employing the same

Recombinant PR-3 and compositions thereof

Method of solubilizing, purifying, and refolding protein

The present invention is directed to an isolated and purified, recombinant, unglycosylated and dimeric CSF-1, the dimeric CSF-1 being biologically active and essentially endotoxin and pyrogen-free, the dimeric CSF-1 consisting essentially of two monomeric human CSF-1 subunits. The present invention is further directed to pharmaceutical compositions comprising the same.

Recombinant human CSF-1 dimer and compositions thereof

A colony stimulating factor, CSF-1, is a lymphokine useful in regulating the immune system, is a lymphokine useful in overcoming the immunosuppression induced by chemotherapy or resulting from other causes. CSF-1 is obtained in usable amounts by recombinant methods, including cloning and expression of the murine and human DNA sequences encoding this protein. Both &ldquo;long&rdquo; and &ldquo;short&rdquo; forms of this protein and muteins corresponding to the cDNA-encoded forms are disclosed.

DNA encoding N&nabla;2 CSF-1 (short form) and carboxy truncated fragment thereof

A colony stimulating factor, CSF-1, is a lymphokine useful in regulating the immune system. is a lymphokine useful in overcoming the immunosuppression induced by chemotherapy or resulting from other causes. CSF-1 is obtained in usable amounts by recombinant methods, including cloning and expression of the murine and human DNA sequences encoding this protein. Both 'long' and 'short' forms of this protein and muteins corresponding to the cDNA-encoded forms are disclosed.

Point mutants of N.gradient.2 CSF-1 and carboxy truncated fragments

A colony stimulating factor, CSF-1, is a lymphokine useful in regulating the immune system is a lymphokine useful in overcoming the immunosuppression induced by chemotherapy or resulting from other causes. CSF-1 is obtained in usable amounts by recombinant methods, including cloning and expression of the murine and human DNA sequences encoding this protein. Both 'long' and 'short' forms of this protein and muteins corresponding to the cDNA-encoded forms are disclosed.

DNA encoding NV2 (long form) and carboxy truncated fragments thereof

N.gradient.2-CSF-1(long form) and carboxy truncated fragments thereof

N.gradient.2 CSF-1 (short form) and carboxy truncated fragments thereof

A purified glycoprotein complex of over 1200 kD apparent native molecular weight having a sedimentation value of approtely 25S and having the ability to selectively bind human Mac-2 or interfere with PHA activation of lymphocytes, DNA sequences that encode the protein, and expression systems for expressing it, thus providing for medicaments that are useful for treating or diagnosing diseases, including cancer, infectious disease, and diseases of the immune system.

Secreted mac-2-binding glycoprotein

The present invention is directed to methods for crystallizing macrophage colony stimulating factor. The present invention is also directed to methods for designing and producing M-CSF agonists and antagonists using information derived from the crystallographic structure of M-CSF. The invention is also directed to methods for screening M-CSF agonists and antagonists. In addition, the present invention is directed to an isolated, purified, soluble and functional M-CSF receptor.

Identification of M-CSF agonists and antagonists

Growing community of inventors

San Rafael, CA, United States of America

Robert F Halenbeck